haloperidol has been researched along with Abnormal Movements in 39 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD)." | 8.02 | Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ( Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC, 2021) |
| "Effect of administration of Rice bran oil (RBO) was evaluated on haloperidol elicited tardive dyskinesia in rats." | 7.83 | Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2016) |
| "Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics." | 5.62 | PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ( Guimarães, FS; Prado, DDS; Sonego, AB, 2021) |
| "Animal models of haloperidol (HAL)-induced neurotoxicity and orofacial dyskinesia (OD) have long been used to study human tardive dyskinesia (TD)." | 4.02 | Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia. ( Fang, CH; Lin, YW; Soung, HS; Tseng, HC; Wang, MH; Yang, CC, 2021) |
| "Haloperidol (Hal) is an antipsychotic related to movement disorders." | 3.91 | Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. ( Burger, ME; da Silva Barcelos, RC; Kronbauer, M; Metz, VG; Milanesi, LH; Roversi, K; Rubert Rossato, D, 2019) |
| "Effect of administration of Rice bran oil (RBO) was evaluated on haloperidol elicited tardive dyskinesia in rats." | 3.83 | Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2016) |
| "Haloperidol treatment reduced the locomotor activity and increased the number of VCM in rats." | 1.72 | Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones. ( Boeck, CR; da Silva Schmitz, I; de Lima, VB; Dorneles, GP; Mezzomo, NF; Peroza, LR; Romao, PRT; Schaffer, LF, 2022) |
| "Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics." | 1.62 | PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice. ( Guimarães, FS; Prado, DDS; Sonego, AB, 2021) |
| "We present a case of hemichorea/hemiballism, a rare complication of hyperglycemia." | 1.51 | [Hemichorea/hemiballism a rare complication of hyperglycemia]. ( Kataja Knight, A; Magnusson, P; Sjöholm, Å; Tidehag, L, 2019) |
| "Haloperidol (1 mg/kg, ip) was administered for 21 successive days to induce orofacial dyskinesia and catalepsy." | 1.48 | Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. ( Dhingra, D; Gahalain, N; Goswami, S, 2018) |
| "Non-ketotic hyperglycaemic hemichorea-hemiballismus (NHHH) is commonly seen among elderly Asian women with type 2 diabetes mellitus." | 1.48 | Paediatric non-ketotic hyperglycaemic hemichorea-hemiballismus. ( Benitez, JAEL; Sacro, CAL; Suratos, CTR; Urquiza, SC, 2018) |
| "Mice treated with haloperidol showed an increase in microglial activation and inflammatory mediators in the striatum." | 1.48 | Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. ( Cunha, TM; Del Bel, EA; Guimarães, FS; Prado, DS; Raisman-Vozari, R; Sepulveda-Diaz, JE; Sonego, AB; Tirapelli, CR; Vale, GT, 2018) |
| "The hemiballismus was significant and persistent, resulting in profound functional disability." | 1.46 | Management of Severe Hemiballismus: Treatment Challenges in the Acute Inpatient Rehabilitation Setting: A Case Presentation. ( Altschuler, EL; Brighenti, A; Hodde, M; Rowe, KE; Surapaneni, K; Terrigno, P, 2017) |
| "They also displayed reduced abnormal involuntary movements after apomorphine and quinpirole treatment in the mouse dyskinesia model of Parkinson's disease." | 1.40 | G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. ( Ferger, B; Hengerer, B; Oeckl, P, 2014) |
| "Although persistent involuntary movements caused by cerebrovascular diseases mostly in middle-aged patients are well known, transient involuntary movements are an unusual manifestation of cerebrovascular diseases." | 1.35 | [Case of reversible ischemic neurological deficit presented as hemiballism]. ( Ishizaka, S; Kawahara, I; Matsuo, Y; Nakamoto, M; Tokunaga, Y; Yagi, N, 2008) |
| "Three cases of hemichorea-hemiballismus (HC-HB) associated with nonketotic hyperglycemia were reported." | 1.35 | Hemichorea-hemiballismus associated with nonketotic hyperglycemia: a possible role of inflammation. ( Deng, BQ; Wang, JH; Wang, ZK; Wu, T; Zhang, P; Zhang, YW, 2009) |
| "Hemiballismus is characterized by the abrupt onset of violent proximal flinging movements, affecting the limbs, neck and trunk on one side of the body." | 1.32 | Hemiballismus following general anesthesia. A case report. ( Buraczyńska, K; Pilarczyk, M; Sagan, M; Stelmasiak, Z; Tynecka, M, 2003) |
| "We report eight cases of hemiballism." | 1.31 | [Hemiballism: report of eight cases]. ( Coral, P; Teive, HA; Werneck, LC, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 15 (38.46) | 29.6817 |
| 2010's | 17 (43.59) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Mezzomo, NF | 1 |
| da Silva Schmitz, I | 1 |
| de Lima, VB | 1 |
| Dorneles, GP | 1 |
| Schaffer, LF | 1 |
| Boeck, CR | 1 |
| Romao, PRT | 1 |
| Peroza, LR | 1 |
| Uslu, ET | 1 |
| Mengi, M | 1 |
| Beyazyüz, E | 1 |
| Çelikkol, A | 1 |
| Albayrak, Y | 1 |
| Wang, MH | 2 |
| Yang, CC | 1 |
| Tseng, HC | 2 |
| Fang, CH | 1 |
| Lin, YW | 1 |
| Soung, HS | 2 |
| Sonego, AB | 2 |
| Prado, DDS | 1 |
| Guimarães, FS | 2 |
| Dhingra, D | 1 |
| Goswami, S | 1 |
| Gahalain, N | 1 |
| Benvegnú, DM | 1 |
| Roversi, K | 3 |
| Barcelos, RCS | 1 |
| Trevizol, F | 1 |
| Pase, CS | 1 |
| Segat, HJ | 1 |
| Dias, VT | 2 |
| Savian, AL | 1 |
| Piccoli, BL | 1 |
| Piccolo, J | 1 |
| Dutra-Filho, CS | 1 |
| Emanuelli, T | 1 |
| de Bona da Silva, C | 1 |
| Beck, RCR | 1 |
| Burger, ME | 3 |
| Chen, CN | 1 |
| Chang, KC | 1 |
| Cho, HS | 1 |
| Hong, CT | 1 |
| Chan, L | 1 |
| Suratos, CTR | 1 |
| Benitez, JAEL | 1 |
| Urquiza, SC | 1 |
| Sacro, CAL | 1 |
| Prado, DS | 1 |
| Vale, GT | 1 |
| Sepulveda-Diaz, JE | 1 |
| Cunha, TM | 1 |
| Tirapelli, CR | 1 |
| Del Bel, EA | 1 |
| Raisman-Vozari, R | 1 |
| Xiao, F | 1 |
| Liu, M | 1 |
| Wang, XF | 1 |
| Tidehag, L | 1 |
| Kataja Knight, A | 1 |
| Magnusson, P | 1 |
| Sjöholm, Å | 1 |
| Kronbauer, M | 2 |
| Metz, VG | 2 |
| Milanesi, LH | 1 |
| Rubert Rossato, D | 1 |
| da Silva Barcelos, RC | 2 |
| Oeckl, P | 1 |
| Hengerer, B | 1 |
| Ferger, B | 1 |
| McLay, SV | 1 |
| MacDonald, SP | 1 |
| Samad, N | 1 |
| Haleem, MA | 1 |
| Haleem, DJ | 1 |
| de David Antoniazzi, CT | 1 |
| Hodde, M | 1 |
| Rowe, KE | 1 |
| Surapaneni, K | 1 |
| Terrigno, P | 1 |
| Brighenti, A | 1 |
| Altschuler, EL | 1 |
| Lin, CJ | 1 |
| Huang, P | 1 |
| Kawahara, I | 1 |
| Ishizaka, S | 1 |
| Yagi, N | 1 |
| Nakamoto, M | 1 |
| Matsuo, Y | 1 |
| Tokunaga, Y | 1 |
| Wang, JH | 1 |
| Wu, T | 1 |
| Deng, BQ | 1 |
| Zhang, YW | 1 |
| Zhang, P | 1 |
| Wang, ZK | 1 |
| Marchione, P | 1 |
| Vento, C | 1 |
| Marianetti, M | 1 |
| Romeo, T | 1 |
| Amabile, GA | 1 |
| Giacomini, P | 1 |
| Baik, JS | 1 |
| You, SJ | 1 |
| Lee, MS | 1 |
| Kasture, S | 1 |
| Pawar, A | 1 |
| Kasture, A | 1 |
| Foddis, C | 1 |
| Frau, MA | 1 |
| Maxia, A | 1 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Gupta, S | 1 |
| Linn, GS | 1 |
| Negi, SS | 1 |
| Gerum, SV | 1 |
| Javitt, DC | 1 |
| VAISBERG, M | 1 |
| SAUNDERS, JC | 1 |
| Pilarczyk, M | 1 |
| Buraczyńska, K | 1 |
| Sagan, M | 1 |
| Tynecka, M | 1 |
| Stelmasiak, Z | 1 |
| Nagai, C | 1 |
| Chu, NS | 1 |
| Dekundy, A | 1 |
| Pietraszek, M | 1 |
| Schaefer, D | 1 |
| Cenci, MA | 1 |
| Danysz, W | 1 |
| Wehrschuetz, M | 1 |
| Simbrunner, J | 1 |
| Enzinger, C | 1 |
| Ebner, F | 1 |
| Verma, R | 1 |
| Agarwal, A | 1 |
| Kar, AM | 1 |
| Hans, ML | 1 |
| Maxwell, C | 1 |
| Ehrlichman, RS | 1 |
| Metzger, K | 1 |
| Liang, Y | 1 |
| Siegel, SJ | 1 |
| Lowman, AM | 1 |
| Korenyi, C | 1 |
| Whittier, JR | 1 |
| Oerlemans, WG | 1 |
| Moll, LC | 1 |
| Eichhammer, P | 1 |
| Albus, M | 1 |
| Borrmann-Hassenbach, M | 1 |
| Schoeler, A | 1 |
| Putzhammer, A | 1 |
| Frick, U | 1 |
| Klein, HE | 1 |
| Rohrmeier, T | 1 |
| Coral, P | 1 |
| Teive, HA | 1 |
| Werneck, LC | 1 |
3 reviews available for haloperidol and Abnormal Movements
| Article | Year |
|---|---|
Hemichorea after hyperglycemia correction: A case report and a short review of hyperglycemia-related hemichorea at the euglycemic state.
Topics: Aged; Anti-Dyskinesia Agents; Diagnosis, Differential; Dyskinesias; Haloperidol; Humans; Hyperglycem | 2018 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
[Progress in diagnosis of and therapy for diabetic choreic movement and ballismus].
Topics: Anti-Dyskinesia Agents; Basal Ganglia; Chorea; Diabetes Complications; Diabetes Mellitus; Dyskinesia | 2004 |
36 other studies available for haloperidol and Abnormal Movements
| Article | Year |
|---|---|
Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones.
Topics: Animals; Dyskinesias; Haloperidol; Isoflavones; Male; Neuroinflammatory Diseases; Rats; Rats, Wistar | 2022 |
The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats.
Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Dyskinesias; Fluvoxamine; Haloperi | 2023 |
Naringin Ameliorates Haloperidol-Induced Neurotoxicity and Orofacial Dyskinesia in a Rat Model of Human Tardive Dyskinesia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dyskinesias; Flavanones; Haloperidol; Humans; | 2021 |
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antipsychotic Agents; Behavior, Animal; Cannabidiol; Cognitive Dysf | 2021 |
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
Topics: Animals; Behavior, Animal; Brain; Catalepsy; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Glutat | 2018 |
Effects of Fish and Grape Seed Oils as Core of Haloperidol-Loaded Nanocapsules on Oral Dyskinesia in Rats.
Topics: Animals; Anti-Dyskinesia Agents; Biological Products; Cell Survival; Dyskinesias; Fish Oils; Fishes; | 2018 |
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesias; Glutamates; Haloperidol; Lipid Peroxi | 2018 |
Paediatric non-ketotic hyperglycaemic hemichorea-hemiballismus.
Topics: Adolescent; Anti-Dyskinesia Agents; Blood Glucose; Chorea; Clonazepam; Diabetes Mellitus, Type 1; Dy | 2018 |
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.
Topics: Animals; Antioxidants; Antipsychotic Agents; Behavior, Animal; Brain; Cannabidiol; Corpus Striatum; | 2018 |
Involuntary choreiform movements in a diabetic patient.
Topics: Anti-Dyskinesia Agents; Basal Ganglia; Blood Glucose; Clonazepam; Diabetes Mellitus, Type 2; Dyskine | 2019 |
[Hemichorea/hemiballism a rare complication of hyperglycemia].
Topics: Aged, 80 and over; Anti-Dyskinesia Agents; Basal Ganglia; Chorea; Dyskinesias; Female; Haloperidol; | 2019 |
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances.
Topics: Animals; Antipsychotic Agents; Brain; Calcium Channel Blockers; Calcium Channels, L-Type; Corpus Str | 2019 |
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cyclic AMP; Disease Models, Ani | 2014 |
Hyper-dopaminergic ballismus and respiratory dyskinesia treated with intravenous haloperidol.
Topics: Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine Agents; Dyskinesias; Haloperidol; Humans; Inj | 2014 |
Report: Protective effects of rice bran oil in haloperidol-induced tardive dyskinesia and serotonergic responses in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Dyskinesias; Haloperidol; Hyd | 2016 |
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Brain; Catalepsy; Chick Embryo; Disease Models, | 2017 |
Management of Severe Hemiballismus: Treatment Challenges in the Acute Inpatient Rehabilitation Setting: A Case Presentation.
Topics: Combined Modality Therapy; Dyskinesias; Follow-Up Studies; Haloperidol; Humans; Inpatients; Male; Mi | 2017 |
Delayed onset diabetic striatopathy: Hemichorea-hemiballism one month after a hyperglycemic episode.
Topics: Aged; Anti-Dyskinesia Agents; Anticonvulsants; Clonazepam; Diabetes Complications; Diagnosis, Differ | 2017 |
[Case of reversible ischemic neurological deficit presented as hemiballism].
Topics: Aged; Chlorpromazine; Diagnostic Imaging; Dyskinesias; Haloperidol; Humans; Ischemic Attack, Transie | 2008 |
Hemichorea-hemiballismus associated with nonketotic hyperglycemia: a possible role of inflammation.
Topics: Aged, 80 and over; Anti-Dyskinesia Agents; Autoimmune Diseases of the Nervous System; Chorea; Corpus | 2009 |
Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
Topics: Aged; Anti-Dyskinesia Agents; Anticonvulsants; Antihypertensive Agents; Ataxia; Cerebellum; Dose-Res | 2009 |
Bilateral ballism after herpes encephalitis with thalamic lesion.
Topics: Acyclovir; Adrenal Cortex Hormones; Anti-Dyskinesia Agents; Antiviral Agents; Brain; Child, Preschoo | 2010 |
Effect of ethanolic extract of Rubia peregrina L. (Rubiaceae) on monoamine-mediated behaviour.
Topics: Adrenergic Agents; Animals; Catalepsy; Dopamine Agents; Dyskinesias; Haloperidol; Lithium Compounds; | 2011 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Behavior, Animal; Cebus; Clozapine; Disease Mod | 2003 |
TREATMENT OF DYSKINESIAS INCLUDING HUNTINGTON'S CHOREA WITH THIOPROPAZATE AND R-1625.
Topics: Chorea; Dyskinesias; Haloperidol; Humans; Huntington Disease; Movement Disorders; Phenothiazines; Tr | 1963 |
Hemiballismus following general anesthesia. A case report.
Topics: Anesthesia, General; Anticonvulsants; Antipsychotic Agents; Brain Ischemia; Clonazepam; Dyskinesias; | 2003 |
Orolingual dyskinesia in central pontine myelinolysis.
Topics: Anti-Dyskinesia Agents; Brain; Diabetes Complications; Dyskinesias; Female; Haloperidol; Humans; Lip | 2004 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, An | 2006 |
[Hemiballism-hemichorea syndrome].
Topics: Anti-Dyskinesia Agents; Brain Diseases; Cerebrovascular Circulation; Chorea; Drug Therapy, Combinati | 2007 |
Hemichorea resulting from single enhancing computed tomography lesion.
Topics: Albendazole; Anti-Dyskinesia Agents; Anticestodal Agents; Child; Chorea; Dyskinesias; Female; Follow | 2006 |
Evaluation of in vitro release and in vivo efficacy of mPEG-PLA-haloperidol conjugate micelle-like structures.
Topics: Animals; Anti-Dyskinesia Agents; Delayed-Action Preparations; Drug Delivery Systems; Dyskinesia, Dru | 2007 |
Dyskinesia analysis. Histogram analysis of cineseismograms of human dyskinesia.
Topics: Aged; Anti-Dyskinesia Agents; Dyskinesias; Haloperidol; Humans; Huntington Disease; Male; Mesoridazi | 1974 |
Non-ketotic hyperglycemia in a young woman, presenting as hemiballism-hemichorea.
Topics: Acute Disease; Adult; Anti-Dyskinesia Agents; Brain; Chorea; Diagnosis, Differential; Dyskinesias; F | 1999 |
Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia.
Topics: Acute Disease; Akathisia, Drug-Induced; Amino Acid Substitution; Antipsychotic Agents; Dyskinesias; | 2000 |
[Hemiballism: report of eight cases].
Topics: Adolescent; Adult; Aged; Anti-Dyskinesia Agents; Diabetes Complications; Dyskinesias; Female; Halope | 2000 |